- socially bharat
- November 14, 2024
PopVax Announces that the U.S. National Institute of Allergy and Infectious Diseases will Conduct and Sponsor the U.S.-based Phase I Clinical Trial of PopVax’s Next-Generation mRNA-LNP COVID-19 Vaccine as part of the U.S. Government’s Project NextGen
MUMBAI, India & HYDERABAD, India: PopVax, an Indian full-stack biotechnology company developing novel mRNA vaccines and therapeutics using machine learning-enabled computational